fruquintinib + chemotherapy

Fruquintinib is a potent and highly selective oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, which are critical mediators of tumor angiogenesis. In the context of clinical research led by Fudan University, specifically the FRU-RAS trial, fruquintinib is administered in combination with standard second-line chemotherapy regimens, such as mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluorouracil) or FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil). This combination therapy is designed to treat patients with RAS-mutant metastatic colorectal cancer (mCRC) by providing a dual mechanism of anti-angiogenic and cytotoxic activity. The regimen aims to offer a more effective therapeutic alternative to the current standard of care, bevacizumab plus chemotherapy, by leveraging fruquintinib's high selectivity and potency against VEGFR targets.

Other names

fruquintinib plus chemotherapyfruquintinib + mFOLFOX6fruquintinib + FOLFIRI